证券代码：300896 证券简称：爱美客 公告编号：2025-018 号 爱美客技术发展股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 爱美客技术发展股份有限公司（以下简称"公司"）于 2025 年 3 月 19 日召 开了第三届董事会第十七次会议，决定于 2025 年 4 月 18 日（星期五）下午 15:00 召开 2024 年度股东大会（以下简称"本次会议"）。 现将会议的有关情况通知如下： 一、召开会议的基本情况 本次股东大会的召集程序符合有关法律、行政法规、部门规章、规范性文件、 深圳证券交易所业务规则和《公司章程》等有关规定。 4、会议召开的日期、时间： （1）会议召开时间：2025 年 4 月 18 日（星期五）15:00 （2）网络投票时间：2025 年 4 月 18 日（星期五） 1 通过深圳证券交易所交易系统投票的时间为 2025 年 4 月 18 日 9:15- 9:25,9:30-11:30,13:00-15:00 ； 通 过 深 交 所 互 联 网 投 票 系 统 （http:// ...

证券代码：300896 证券简称：爱美客 公告编号：2025-008 号 爱美客技术发展股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 爱美客技术发展股份有限公司（以下简称"公司""爱美客"）第三届监事 会第十三次会议于 2025 年 3 月 19 日上午 11:00 在公司会议室以现场会议的方式 召开。会议通知已于 2025 年 3 月 7 日通过邮件和电话的方式送达各位监事。本 次会议应到监事 3 人，实到监事 3 人。本次会议的召开符合《中华人民共和国公 司法》《公司章程》以及有关法律、法规的规定。会议由公司监事会主席陈重主 持。 二、监事会会议审议情况 与会监事对本次会议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于〈公司 2024 年度监事会工作报告〉的议案》 本议案尚需提交股东大会审议。 第三届监事会第十三次会议决议公告 表决结果：同意3票，反对0票，弃权0票。 2、审议通过了《关于〈公司2024年度报告〉及〈摘要〉的议案》 本议案尚需提交股东大会审议。 表决结果：同意3票，反对0票，弃权0票 ...

证券代码：300896 证券简称：爱美客 公告编号：2025-007 号 爱美客技术发展股份有限公司 第三届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 爱美客技术发展股份有限公司（以下简称"公司"）第三届董事会第十七次 会议于 2025 年 3 月 19 日上午 10:00 在公司会议室以现场方式召开。本次会议应 到董事 9 人，实到董事 9 人。会议通知已于 2025 年 3 月 7 日通过邮件和电话的 方式送达各位董事。 本次会议的召开符合《中华人民共和国公司法》《公司章程》以及有关法律、 法规的规定。会议由公司董事长简军主持，监事和高级管理人员列席了会议。 二、董事会会议审议情况 与会董事对本次会议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于〈公司 2024 年度总经理工作报告〉的议案》 1 报告内容详见《2024 年度报告》中"第四节 公司治理"之"八、报告期内 董事履行职责的情况"、之"九、董事会下设专门委员会在报告期内的情况"部 分。 本议案经董事会审议通过后尚需提交股东大 ...

Financial Performance - The company's operating revenue for 2024 reached ¥3,025,668,449.47, representing a 5.45% increase compared to ¥2,869,347,231.89 in 2023[20]. - Net profit attributable to shareholders for 2024 was ¥1,957,596,837.74, up by 5.33% from ¥1,858,475,302.54 in 2023[20]. - The net profit after deducting non-recurring gains and losses was ¥1,871,694,735.68, reflecting a 2.20% increase from ¥1,831,328,790.94 in 2023[20]. - The net cash flow from operating activities decreased by 1.38% to ¥1,927,174,523.41 from ¥1,954,070,643.13 in 2023[20]. - Total assets at the end of 2024 amounted to ¥8,340,486,256.64, a 21.72% increase from ¥6,852,360,636.01 in 2023[20]. - Net assets attributable to shareholders increased by 22.83% to ¥7,797,060,228.15 from ¥6,347,942,275.99 in 2023[20]. - The basic earnings per share for 2024 was ¥6.50, a 15.69% increase from ¥5.84 in 2023[20]. - The diluted earnings per share also stood at ¥6.50, reflecting a 15.69% increase from ¥5.84 in 2023[20]. - The company reported a total of ¥85,902,102.06 in non-recurring gains for 2024, compared to ¥27,146,511.60 in 2023[26]. Market Position and Growth - The Chinese medical beauty market is expected to grow at a rate of approximately 10% in 2024, driven by increasing penetration and diversified quality demands[1]. - The company has maintained the number one market share in the domestic hyaluronic acid-based dermal fillers market since 2018[3]. - The penetration rate of medical beauty in China increased from 2.4% in 2014 to 4.5% in 2023, indicating significant growth potential compared to developed countries with rates around 17.8%[55]. - The domestic medical beauty market is expected to grow at a rate of approximately 10% in 2024, driven by increasing consumer income and acceptance of medical beauty services[54]. - The Chinese medical beauty market is projected to reach ¥638.2 billion by 2030, with a compound annual growth rate (CAGR) of 14.5% from 2021 to 2030[125]. Research and Development - The company invested approximately 30,368,400 CNY in R&D, accounting for 10.04% of operating revenue[45]. - The company holds 163 valid authorized patents, including 49 invention patents[45]. - The company is actively pursuing market expansion through new product development and acquisitions, enhancing its competitive position in the aesthetic medical field[78][82]. - The company is in the clinical trial phase for several new products, including the second-generation implant line and medical sodium hyaluronate gel, aimed at expanding market share and revenue[82][83]. - The company is focusing on the development of recombinant proteins and peptides in the biomedical field to enhance its product offerings[129]. Corporate Governance - The company’s actual governance situation complies with relevant laws and regulations, ensuring a robust internal management structure[145]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management[150]. - The company maintains an independent operational structure, with no interference from controlling shareholders in decision-making[147]. - The company has independent financial management, with no shared bank accounts with controlling shareholders[162]. - The company’s governance structure complies with the requirements of the Corporate Governance Code and relevant regulations[155]. Investment and Funding - The total fundraising amount raised by the company was RMB 357,175.40 million, with a net amount of RMB 343,513.38 million after deducting issuance costs of RMB 13,662.02 million[111]. - The company has achieved a usage rate of 60.49% for the total raised funds, with 3.77% of the total amount remaining unused[109]. - The company has committed to invest a total of 193,494.22 million in various projects, with 122,241.77 million allocated to new research and development centers[114]. - The company has raised 85,565.26 million for investment and acquisition purposes, enhancing its market position[114]. - The company plans to use up to RMB 12 billion of temporarily idle raised funds for cash management, including purchasing structured deposits and large certificates of deposit[116]. Product Development and Innovation - The company has launched 11 Class III medical device products, including "Yimei," "Aifulai," "Baonida," "Haitai," "Jinlian," and "Rubai Tianzi," focusing on skin injection, filling, and treatment[39]. - The company emphasizes technological innovation, establishing a product technology transformation platform for biodegradable new materials[4]. - The company has successfully commercialized a series of skin fillers based on sodium hyaluronate and polylactic acid, with ongoing development of recombinant proteins and peptides[61]. - The company is exploring acquisition opportunities to enhance its product portfolio, targeting firms with complementary technologies[171]. - The company plans to enhance brand image and expand market presence by focusing on technological innovation and customer needs in 2025[131]. Employee and Management - The total number of employees at the end of the reporting period is 1,223, including 793 at the parent company and 430 at major subsidiaries[194]. - The company has 542 sales personnel, 293 technical staff, and 229 production workers, contributing to a diverse professional structure[195]. - The company established a comprehensive performance management system linked to a flexible compensation structure, ensuring employee interests are safeguarded[196]. - In 2024, the company trained 1,041 employees, with an average training duration of 50.05 hours per employee[198]. - The total remuneration paid to directors, supervisors, and senior management in 2024 amounted to CNY 17.088 million, including CNY 560,400 for independent directors[184].

重要提示： 公司拟以 2024 年年末总股本 302,592,061 股扣除公司回购专用证券账户持 有的股份 1,165,874 股后的 301,426,187 股为基数，向全体股东每 10 股派发现 金股利 38 元（含税），合计派发现金股利 114,541.95 万元（含税）。本年度公 司不以资本公积金转增股本，不送红股。 一、审议程序 爱美客技术发展股份有限公司（以下简称"公司"）于 2025 年 3 月 19 日召 开第三届董事会第十七次会议、第三届监事会第十三次会议，审议通过了《关于 公司 2024 年度利润分配预案的议案》，本议案尚需提交公司 2024 年度股东大会 审议。 证券代码：300896 证券简称：爱美客 公告编号：2025-009 号 爱美客技术发展股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、2024 年度利润分配预案基本情况 经容诚会计师事务所（特殊普通合伙）审计，公司 2024 年度合并报表归属 于母公司所有者的净利润为 195,759.68 万元，其中母公司实现净利润 ...

商贸零售行业周报：国新办3/17召开提振消费发布 会关注新消费&顺周期 爱美客拟控股收购REGEN BIOTECH 核心观点：当前在提振消费核心政策催化下持续看好顺周期标的弹性，重视以下几条主线。 生育政策。3/5 两会政府工作报告中明确将制定促进生育政策，发放育儿补贴后；呼和浩特市3/13 发布大力度生育补贴政策，后续各地生育补贴有望陆续推出形成多点催化，关注爱婴室、孩子王、润本 股份、上美股份等；顺周期背景下关注医美、新消费在持续政策催化下高弹性机会，医美、新消费板块 因具备显著财富效应而在顺周期行情中具备最强估值弹性，核心关注爱美客、锦波生物、爱婴室、老铺 黄金、名创优品、布鲁可、潮宏基等； 美护作为消费行业中属于同时具备强韧性及强成长性的板块有望在顺周期行情中优先受益，其中核 心关注确定性高增龙头业绩超预期兑现机会，关注巨子生物、丸美生物、毛戈平、若羽臣、润本股份等 重视政策中明确的主题性行情机会。 AI+消费，政策强调将持续推进"AI+消费"以开辟高成长性消费新赛道，未来关注AI 对整个消费模 式带来的深刻变革：关注AI+眼镜博士眼镜、明月镜片；AI+运动KEEP、英派斯；AI+电商值得买、若 羽臣 ...

星标 ★ IPO日报 精彩文章第一时间推送 近期， 爱美客技术发展股份有限公司（下称" 爱美客"）发布公告，拟通过持股70%的子公司Imeik International Limited （ 下称" 爱美客国际" ） 收 购韩国REGEN Biotech，Inc．公司（下称"韩国REGEN"）85%的股权，交易金额约为1.90亿美元（约合人民币13.86亿元）。 收购完成后，爱美客将持有韩国REGEN59.5%股权，将后者纳入合并报表。值得注意的是，由于 江苏吴中医药发展股份有限公司（下称" 江苏吴中"） 拥有韩国REGEN 主要产品， 艾塑菲童颜针 在中国的独家代理权（有效期至2032年8月28日），这意味着，如果爱美客成功收购，它还将因代理权 的问题与江苏吴中打交道。 具体投资过程是，爱美客和首瑞香港分别出资70%和30%，成立了爱美客国际有限公司，作为本次交易的收购主体，股权穿透来看，爱美客实际花费1.33 亿美元（折合人民币9.7亿元）购买韩国REGEN公司59.5%股权，而公告中85%股权的剩余部分（约25.5%），则由首瑞香港出资0.57亿美元收购。 此外，公司还宣布，如果本次收购能够得到批准并完 ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [4]. Core Views - The company has acquired 85% of REGEN Biotech, Inc., a leading South Korean medical aesthetics company, which is expected to create synergies in research, production, and sales [1][3]. - The acquisition is a strategic move to enhance the company's international presence and strengthen its market position in the medical aesthetics sector [8]. - The company's revenue is projected to grow significantly, with expected revenues of 3,159 million yuan in 2024, 3,743 million yuan in 2025, and 4,495 million yuan in 2026, reflecting a growth rate of 10.1%, 18.5%, and 20.1% respectively [1][9]. Financial Summary - The company's revenue for 2022 was 1,939 million yuan, with a year-on-year growth rate of 33.9%. For 2023, the revenue is expected to reach 2,869 million yuan, representing a growth rate of 48.0% [1][9]. - The net profit attributable to the parent company is projected to increase from 1,264 million yuan in 2022 to 2,072 million yuan in 2024, with corresponding growth rates of 31.9% and 11.5% [1][9]. - The company's return on equity (ROE) is expected to remain strong, with values of 28.6% in 2023 and around 25% in the following years [1][9]. Product and Market Position - REGEN Biotech, Inc. has developed two key products, AestheFill and PowerFill, which are recognized for their safety and effectiveness in the medical aesthetics market. AestheFill has received approval in 34 countries, while PowerFill has been approved in 24 countries [2]. - The company plans to leverage the acquired company's products to enhance its international market presence, particularly with AestheFill now approved for sale in China [3][8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The report highlights that the company, Aimeike, plans to acquire a majority stake (85%) in the South Korean company Regen Biotech for a total consideration of $190 million. This acquisition is a strategic move to enhance Aimeike's international presence and strengthen its leading position in the aesthetic injection market [6][8]. - The core products of Regen, AestheFill and PowerFill, have received regulatory approvals in multiple countries, which will support Aimeike's international expansion. The new production facility in South Korea is expected to commence operations in Q2 2025, potentially driving revenue and profit growth [6][8]. - The acquisition is anticipated to create significant shareholder value in the medium to long term, facilitating Aimeike's transition from a domestic leader to an international giant in the aesthetic medicine sector [8]. Financial Projections - Revenue projections for Aimeike from 2024 to 2026 are estimated at 3.449 billion, 4.208 billion, and 5.142 billion yuan, respectively. The net profit attributable to the parent company is projected to be 2.189 billion, 2.662 billion, and 3.226 billion yuan for the same period [9][10]. - The report indicates that the price-to-earnings (P/E) ratios for 2024, 2025, and 2026 are expected to be 27.8, 22.8, and 18.9, respectively, reflecting a positive outlook on the company's growth and profitability [9][10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The report highlights that the acquisition of Korean Regen Biotech by the company is a significant step in its internationalization strategy, which will help solidify its leading position in the aesthetic injection market [6][8] - The core products of Regen, AestheFill and PowerFill, have received regulatory approvals in multiple countries, providing strong support for the company's international expansion [8] - The new production facility in Korea is expected to commence operations in the second quarter of 2025, which will likely drive revenue and profit growth [8] - The acquisition is projected to create greater shareholder value and facilitate the company's transition from a domestic leader to an international giant in the aesthetic industry [8] Financial Projections - Revenue projections for the company from 2024 to 2026 are estimated at 34.49 billion, 42.08 billion, and 51.42 billion respectively, with net profit estimates of 21.89 billion, 26.62 billion, and 32.26 billion [9][10] - The price-to-earnings (P/E) ratios for 2024, 2025, and 2026 are projected to be 27.8, 22.8, and 18.9 respectively [9][10] - The company is expected to maintain a robust growth trajectory, with revenue growth rates of 20.20%, 22.00%, and 22.20% for the years 2024 to 2026 [10][14]